Abstract Title: Formulation comparisons and pharmacokinetics of high specific activity Ultratrace 131I-Iobenguane (mIBG) for therapy Authors: J. F. Kronauge(a1), J. A. Barrett(1), J. Qi(1), H. Mok(1), D. H. Hunter(2), C. Bensimon(4), S. Oelsner(4), J. P. Norenberg(3), T. Anderson(3), S. Gallo(1), S. M. Hiller(1), J. Joyal(1), N. S. Lee(1) and J. W. Babich(1); 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; 2. University of Western Ontario, London, Ontario, Canada; 3. University of New Mexico, Albuquerque, New Mexico and 4. MDS Nordion, Kanata, Ontario, Canada. Reference #: 335357 Publication No.: 1316 - Scientific Poster Session Poster Section: Dosimetry/Radiobiology Posters Session Info: "Meet the Author" II: Neurosciences, General Clinical Specialties, and Radiopharmaceutical Chemistry Posters Monday, June 4 3:15 PM- 4:00 PM Hall E-0-
Abstract Title: A comparison of Iodine-123 and Technetium-99m assays using dose calibrators Authors: D. L. Yokell(a), J. F. Kronauge, C. S. Kao and J. W. Babich; Development, Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts. Reference #: 335015 Publication No.: 1835 - Scientific Poster Session Poster Section: Instrumentation Posters Session Info: "Meet the Author" IV: Instrumentation & Data Analysis Posters Tuesday, June 5 1:15 PM - 2:00 PM Hall E-0-
Abstract Title: Synthesis and evaluation of a series of M(CO)3+ (M=Tc,Re) lisinopril complexes for imaging angiotensin converting enzyme (ACE) Authors: F. J. Femia(a1), K. P. Maresca(1), S. M. Hillier(1), C. N. Zimmerman(1), J. L. Joyal(1), J. A. Barrett(1), T. Coleman(2), O. Aras(2), C. A. Foss(3), M. G. Pomper(3), V. Dilsizian(2), W. C. Eckelman(1) and J. W. Babich(1); 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; 2. Nuclear Medicine, University of Maryland, Baltimore, Maryland and 3. Radiology, Johns Hopkins Medical Institutions, Baltimore, Maryland. Reference #: 331898 Publication No.: 613 - Scientific Paper Session (Oral) Session Info: New Chemistry-Other II Wednesday, June 6 9:45 AM - 11:15 AM Room 145A
On June 3rd, researchers at Molecular Insight also presented preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer. MIP-1072 is designed to target prostate specific membrane antigen (PSMA), a protein found predominantly on prostate tumor cells. The paper, "Molecular Targeting of Prostate Cancer with Small Molecular Inhibitors of Prostate Specific Membrane Antigen," was honored by SNM with the 2007 Berson-Yalow Award for most original scientific abstract.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra(TM), Onalta (TM), Zemiva(TM) and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical result s or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Molecular Insight Pharmaceuticals, Inc.
Priscilla Harlan, 617-492-5554
Vice President, Corporate Communications
& Investor Relations